Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: A prospective 10-year study

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 11, 2001, Pages 1795-1806

  Hirschowitz, B I ^a   Simmons, J ^a   Mohnen, J ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PEPSIN A;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PEPSIN SECRETION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STOMACH ACID SECRETION; STOMACH PH; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PEPSIN A; PROSPECTIVE STUDIES; PROTON PUMPS; TREATMENT OUTCOME; ZOLLINGER-ELLISON SYNDROME;

EID: 0034778914     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01097.x     Document Type: Article

References (35)

1. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h
2. A prospective long-term study of lansoprazole for treatment of Zollinger-Ellison syndrome
3. Duodenal ulcer with unexplained marked basal gastric acid hypersecretion
4. Relationship between fundic endocrine cells and gastric acid secretion in hypersecretory duodenal ulcer diseases
5. Clinical course of nonsurgically treated Zollinger-Ellison Syndrome
6. Surgery to cure the Zollinger-Ellison syndrome
7. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: A prospective study
8. Zollinger-Ellison syndrome: Clinical presentation, pathology, diagnosis, and treatment
9. Appropriate acid suppression for the management of gastroesophageal reflux disease
10. Is there an optimal degree of acid suppression for healing duodenal ulcers?
11. Evaluation of anti-secretory drug therapy of Zollinger-Ellison Syndrome (ZES)
12. Comparative efficacy of lansoprazole and omeprazole on the intragastric pH over a period of 24 hr and on the basal acid output in 9 patients with Zollinger-Ellison (Fr)
13. Diagnosis and management of Zollinger-Ellison syndrome
14. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high
15. Use of omeprazole in Zollinger-Ellison syndrome: A prospective nine-year study of efficacy and safety
16. Prospective study of the long-term efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome
17. Personal review: Alarmism or legitimate concerns about long-term suppression of gastric acid secretion
18. Vagal effects on acid and pepsin secretion and serum gastrin in duodenal ulcer and controls
19. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome acid hypersecretors treated long-term with omeprazole
20. Reflux esophagitis in patients with Zollinger-Ellison syndrome
21. Detailed comparison of basal and food-stimulated gastric acid secretion rates and serum gastrin concentrations in duodenal ulcer patients and normal subjects
22. Esophagitis in ZE and non-ZE patients with acid hypersecretion (BAO > 15 mEq/h) treated prospectively for up to 10 yr with lansoprazole
23. Clinical outcome with long-term (up to 10 yr) lansoprazole treatment of acid hypersecretors (BAO > 15 MM/h) (ZE and non-ZE) - Role of acid, pepsin and H. pylori
24. Pepsin and the esophagus
25. Development of sustained achlorhydria in a patient with Zollinger-Ellison syndrome treated with omeprazole
26. Intractable upper GI ulceration due to ASA in patients who have had surgery for peptic ulcer
27. Brief report: A duodenal gastrinoma in a patient with diarrhea and normal serum gastrin concentrations
28. Normal serum gastrin concentration in gastrinoma
29. Laboratory diagnosi of gastrinoma
30. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa
31. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism
32. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
33. Adaptations of esophageal mucosa to acid and pepsin-induced damage: Role of nitrous oxide and epidermal growth factors
34. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders
35. Cellular basis of pepsinogen secretion